Sign In
Buy AMGN
$345.60
+7.38 (+2.18%)
At Close: Jun 04, 2026
Amgen (AMGN) Q4 Earnings and Revenues Top Estimates
06:11pm, Tuesday, 06'th Feb 2024
Amgen (AMGN) came out with quarterly earnings of $4.71 per share, beating the Zacks Consensus Estimate of $4.66 per share. This compares to earnings of $4.09 per share a year ago.
Amgen's quarterly results top expectations despite Enbrel sales decline
04:43pm, Tuesday, 06'th Feb 2024
Amgen Inc. on Tuesday reported fourth-quarter profits and sales that topped analysts' expectations even as revenues dropped for one of its top sellers, the rheumatoid-arthritis drug Enbrel.
Amgen Dips Despite Beating Fourth-Quarter Sales Expectations
04:16pm, Tuesday, 06'th Feb 2024
Amgen stock dipped late Tuesday after the company beat fourth-quarter sales expectations, noting nine products hit records.
Amgen quarterly profit rises 15% as Horizon deal boosts results
04:05pm, Tuesday, 06'th Feb 2024
Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Thera
Focus: Amgen taking different path to weight loss windfall
06:03am, Tuesday, 06'th Feb 2024
The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's highly-effective Zepbound, but Amgen is taking a unique ap
3 Fantastic Dow Stocks to Buy in February 2024
11:05pm, Monday, 05'th Feb 2024
While the Nasdaq exchange and S&P 500 grabbed the headlines because of the massive run-up by the so-called Magnificent 7 stocks, the Dow Jones Industrial Average plodded on with its Dow stocks to buy.
Promising early data details on Amgen weight-loss drug published
05:04am, Monday, 05'th Feb 2024
Animal and early-stage human trial data for Amgen's experimental obesity drug published in a medical journal showed that it promoted significant weight loss with an acceptable safety profile, the comp
Unlocking Q4 Potential of Amgen (AMGN): Exploring Wall Street Estimates for Key Metrics
10:21am, Thursday, 01'st Feb 2024
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som
Is Amgen Stock a Buy Now?
07:15am, Thursday, 01'st Feb 2024
Amgen's revenue growth hasn't been very good of late. The company is working on rejuvenating its lineup.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Tuesday, 30'th Jan 2024
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 29'th Jan 2024
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma industry to get US government price cut proposals by Thursday
11:35am, Monday, 29'th Jan 2024
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
10:00am, Monday, 29'th Jan 2024
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Can Amgen (AMGN) Keep the Beat Streak Alive in Q4 Earnings?
09:21am, Monday, 29'th Jan 2024
Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Is Amgen a Good Dividend Stock to Buy Right Now?
08:30am, Monday, 29'th Jan 2024
Amgen's earnings are reliable, and derived from a bunch of different medicines. It spends a relatively small proportion of its resources on developing new drugs.
